Your browser doesn't support javascript.
loading
Recombinant measles virus encoding the spike protein of SARS-CoV-2 efficiently induces Th1 responses and neutralizing antibodies that block SARS-CoV-2 variants.
Kwak, Hye Won; Park, Hyo-Jung; Jung, Seo-Yeon; Oh, Eun Young; Park, Sang-In; Kim, Yeonhwa; Park, Hyeong-Jun; Park, Sohyun; Kim, You-Jin; Ko, Hae Li; Lee, Jung-Ah; Won, Hyeran; Hwang, Yun-Ho; Kim, Seo Yeon; Kim, Se Eun; Bae, Seoung Eun; Yoon, Minhyuk; Kim, Jae-Ouk; Song, Manki; Lee, Su Jeen; Seo, Ki-Weon; Lee, Kunse; Kim, Dokeun; Kim, Hun; Lee, Sang-Myeong; Hong, So-Hee; Nam, Jae-Hwan.
Afiliación
  • Kwak HW; Department of Medical and Biological Sciences, The Catholic University of Korea, Gyeonggi-do, Bucheon, Republic of Korea; BK Plus Department of Biotechnology, The Catholic University of Korea, Gyeonggi-do, Bucheon, Republic of Korea; SML biopharm, Gyeonggi-do, Bucheon, Republic of Korea.
  • Park HJ; Department of Medical and Biological Sciences, The Catholic University of Korea, Gyeonggi-do, Bucheon, Republic of Korea; BK Plus Department of Biotechnology, The Catholic University of Korea, Gyeonggi-do, Bucheon, Republic of Korea.
  • Jung SY; Department of R&D, SK bioscience, Pangyoro, Bundang-gu, Republic of Korea.
  • Oh EY; College of Veterinary Medicine, Chungbuk National University, Cheongju 28644, Republic of Korea.
  • Park SI; Division of Research Program, Scripps Korea Antibody Institute, Chuncheon, Kangwon-do, Republic of Korea.
  • Kim Y; College of Veterinary Medicine, Chungbuk National University, Cheongju 28644, Republic of Korea.
  • Park HJ; Department of Medical and Biological Sciences, The Catholic University of Korea, Gyeonggi-do, Bucheon, Republic of Korea; BK Plus Department of Biotechnology, The Catholic University of Korea, Gyeonggi-do, Bucheon, Republic of Korea; SML biopharm, Gyeonggi-do, Bucheon, Republic of Korea.
  • Park S; College of Veterinary Medicine, Chungbuk National University, Cheongju 28644, Republic of Korea.
  • Kim YJ; Division of Infectious Disease Vaccine Research, Center for Vaccine Research, National Institute of Infectious Diseases, National Institute of Health, Republic of Korea.
  • Ko HL; Division of Research Program, Scripps Korea Antibody Institute, Chuncheon, Kangwon-do, Republic of Korea.
  • Lee JA; Division of Infectious Disease Vaccine Research, Center for Vaccine Research, National Institute of Infectious Diseases, National Institute of Health, Republic of Korea.
  • Won H; Division of Infectious Disease Vaccine Research, Center for Vaccine Research, National Institute of Infectious Diseases, National Institute of Health, Republic of Korea.
  • Hwang YH; Division of Infectious Disease Vaccine Research, Center for Vaccine Research, National Institute of Infectious Diseases, National Institute of Health, Republic of Korea.
  • Kim SY; Division of Infectious Disease Vaccine Research, Center for Vaccine Research, National Institute of Infectious Diseases, National Institute of Health, Republic of Korea.
  • Kim SE; Division of Infectious Disease Vaccine Research, Center for Vaccine Research, National Institute of Infectious Diseases, National Institute of Health, Republic of Korea.
  • Bae SE; Science Unit, International Vaccine Institute, Seoul 08826, Republic of Korea.
  • Yoon M; Science Unit, International Vaccine Institute, Seoul 08826, Republic of Korea.
  • Kim JO; Science Unit, International Vaccine Institute, Seoul 08826, Republic of Korea.
  • Song M; Science Unit, International Vaccine Institute, Seoul 08826, Republic of Korea.
  • Lee SJ; Department of R&D, SK bioscience, Pangyoro, Bundang-gu, Republic of Korea.
  • Seo KW; Department of R&D, SK bioscience, Pangyoro, Bundang-gu, Republic of Korea.
  • Lee K; Department of R&D, SK bioscience, Pangyoro, Bundang-gu, Republic of Korea.
  • Kim D; Division of Infectious Disease Vaccine Research, Center for Vaccine Research, National Institute of Infectious Diseases, National Institute of Health, Republic of Korea.
  • Kim H; Department of R&D, SK bioscience, Pangyoro, Bundang-gu, Republic of Korea.
  • Lee SM; College of Veterinary Medicine, Chungbuk National University, Cheongju 28644, Republic of Korea. Electronic address: smlee@chungbuk.ac.kr.
  • Hong SH; Department of Microbiology, College of Medicine, Ewha Womans University, Seoul 07804, Republic of Korea. Electronic address: shhong13@ewha.ac.kr.
  • Nam JH; Department of Medical and Biological Sciences, The Catholic University of Korea, Gyeonggi-do, Bucheon, Republic of Korea; BK Plus Department of Biotechnology, The Catholic University of Korea, Gyeonggi-do, Bucheon, Republic of Korea. Electronic address: jhnam@catholic.ac.kr.
Vaccine ; 41(11): 1892-1901, 2023 03 10.
Article en En | MEDLINE | ID: mdl-36792434
Owing to the rapid spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its variants, the development of effective and safe vaccines has become a priority. The measles virus (MeV) vaccine is an attractive vaccine platform as it has been administered to children for more than 40 years in over 100 countries. In this study, we developed a recombinant MeV expressing the full-length SARS-CoV-2 spike protein (rMeV-S) and tested its efficacy using mouse and hamster models. In hCD46Tg mice, two-dose rMeV-S vaccination induced higher Th1 secretion and humoral responses than one-dose vaccination. Interestingly, neutralizing antibodies induced by one-dose and two-dose rMeV-S immunization effectively blocked the entry of the α, ß, γ, and δ variants of SARS-CoV-2. Furthermore, two-dose rMeV-S immunization provided complete protection against SARS-CoV-2 in the hamster model. These results suggest the potential of rMeV-S as a vaccine candidate for targeting SARS-CoV-2 and its variants.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Vacunas Virales / COVID-19 Límite: Animals / Humans Idioma: En Revista: Vaccine Año: 2023 Tipo del documento: Article Pais de publicación: Países Bajos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Vacunas Virales / COVID-19 Límite: Animals / Humans Idioma: En Revista: Vaccine Año: 2023 Tipo del documento: Article Pais de publicación: Países Bajos